Clinical Trial

Comparison of Serum Myokine Dosages and Imaging Methods in the Evaluation of Sarcopenia in Patients With Hepatocellular Carcinoma

Study acronym: Myomachia
Recruiting
View on ClinicalTrials.gov →
Record status
This record was last updated November 26, 2024 (before its estimated November 22, 2025 completion). Its status may not reflect the trial's current state.
Summary
It is known that some substances present in the blood, called 'myokines,' influence muscle loss. Some may accelerate this loss, while others may prevent it. Inflammatory substances in the blood can also contribute to muscle loss. Sarcopenia is assessed by an imaging technique called 'Skeletal Muscle Mass Index (SMI)' to measure muscle mass. This analysis can be done from radiological examinations. Sarcopenia has a serious impact on patients with hepatocellular carcinoma. It increases the risk of death, cancer recurrence, and decreases the response to treatments. Therefore, the investigators want to determine if blood tests for myokines obtained by simple blood draw can improve the assessment of sarcopenia in this specific setting.
Protocol Amendment History 2 amendments
This ClinicalTrials.gov record has been amended 2 times since 2024-06-20; most recent amendment 2024-11-25.
Status change: Not Yet Recruiting → Recruiting 2024-11-25
Trial Details
NCT Number NCT06475118
Lead Sponsor CHU de Reims
Conditions Sarcopenia, Hepatocellular Carcinoma
Enrollment 139 participants
Start Date 2024-11-22
Primary Completion 2025-11-22 (estimated)
Study Completion 2026-05-22 (estimated)
Updated on ClinicalTrials.gov 2024-11-26